| |
| | Digital therapeutics (DTx) were gaining popularity as tools to help slash the US' $3 trillion annual spending on chronic disease, and the pandemic has vaulted digital therapies into the spotlight. Now, the Teladoc-Livongo megamerger is heating up competition in the DTx space as players race to capture a slice of a market slated to reach $56 billion by 2025.
In The Digital Therapeutics Report, Insider Intelligence unpacks the state of the digital therapeutics (DTx) market. We explore the impact the $18.5 billion Teladoc-Livongo merger has had on competition in the virtual care space, and how the pandemic has catapulted the global DTx market to reach $56 billion over the next five years. We outline the top DTx startups that are ripe for tie-ups, and provide examples of how payers, pharma, and telehealth vendors should benefit from partnering with or acquiring a DTx firm. Finally, we highlight the barriers that are holding back wide-scale adoption of digital therapeutics. | In full, this exclusive report: | | |
| 1 | Discusses the state of the digital therapeutics market, and how the Teladoc-Livongo megamerger shaken it up | | 2 | Explains how pharma companies, payers, and telehealth vendors can benefit from partnering with or acquiring a digital therapeutics firm | | 3 | Takes an in-depth look at the top digital therapeutics startups shaking up the industry today, and what the future looks like for this space |
Get all of these insights and more when you purchase the Digital Therapeutics Report for $995. | | |
| |
| |
| |
0 comments:
Post a Comment